0MH6 Stock Chart & Stats
€160.40
€1.60(1.01%)
At close: 4:00 PM EDT
€160.40
€1.60(1.01%)
Day’s Range― - ―
52-Week Range€109.00 - €176.60
Previous CloseN/A
Volume63.19K
Average Volume (3M)63.40K
Market Cap
€13.66B
Enterprise Value€12.99K
Total Cash (Recent Filing)€1.97B
Total Debt (Recent Filing)€963.20M
Price to Earnings (P/E)26.4
Beta0.85
Next Earnings
Feb 11, 2027EPS Estimate
7.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.20
Shares Outstanding83,814,530
10 Day Avg. Volume42,069
30 Day Avg. Volume63,401
Financial Highlights & Ratios
PEG Ratio0.78
Price to Book (P/B)2.29
Price to Sales (P/S)2.70
P/FCF Ratio9.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€177.50Price Target Upside10.66% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)14.3
Revenue Forecast (FY)€4.45B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent multi-year topline expansion, including a notable 2025 step-up, indicates durable demand across Ipsen's specialty franchises. Sustained revenue growth improves scale economics, supports continued R&D and launches, and lowers execution risk for medium-term commercialization plans.
Free Cash Flow QualityA strong FCF rebound and near-parity with net income in 2025 signal high-quality earnings and healthier cash conversion when achieved. Reliable cash generation enables funding of pipeline investment, strategic partnerships or debt paydown, enhancing financial flexibility over the coming months.
Conservative Capital StructureA low debt-to-equity ratio and growing equity base provide balance-sheet resilience and lower interest burden. This conservative leverage profile preserves capacity for opportunistic M&A or R&D spending and reduces refinancing stress, supporting steady execution over the medium term.
Bears Say
Margin CompressionSustained decline in profitability versus prior years points to structural cost pressures, adverse product mix, or increased competition. Lower margins reduce internal funding for growth, weaken return on incremental capital, and may limit ability to absorb pricing or reimbursement shocks over the next several quarters.
Step-up In Total DebtA material rise in absolute debt, even with still-modest D/E, reduces optionality and elevates interest and refinancing exposure if maintained. Higher leverage can constrain capital allocation, increase financing costs, and magnify downside in weaker cash-flow periods over the medium term.
Volatile Cash ConversionIrregular operating cash conversion and a prior weak FCF year indicate execution and working-capital variability. This volatility complicates planning for R&D, dividends or buybacks, and raises the probability of short-term funding needs or constrained investments if negative swings recur.
Ipsen News
0MH6 FAQ
What was Ipsen’s price range in the past 12 months?
Ipsen lowest share price was €109.00 and its highest was €176.60 in the past 12 months.
What is Ipsen’s market cap?
Ipsen’s market cap is €13.66B.
When is Ipsen’s upcoming earnings report date?
Ipsen’s upcoming earnings report date is Feb 11, 2027 which is in 174 days.
How were Ipsen’s earnings last quarter?
Ipsen released its earnings results on Jul 30, 2026. The company reported €7.33 earnings per share for the quarter, beating the consensus estimate of €6.32 by €1.01.
Is Ipsen overvalued?
According to Wall Street analysts Ipsen’s price is currently Undervalued.
Does Ipsen pay dividends?
Ipsen does not currently pay dividends.
What is Ipsen’s EPS estimate?
Ipsen’s EPS estimate is 7.16.
How many shares outstanding does Ipsen have?
Ipsen has 83,814,530 shares outstanding.
What happened to Ipsen’s price movement after its last earnings report?
Ipsen reported an EPS of €7.33 in its last earnings report, beating expectations of €6.32. Following the earnings report the stock price went down -2.229%.
Which hedge fund is a major shareholder of Ipsen?
Currently, no hedge funds are holding shares in GB:0MH6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ipsen
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the treatment of progressive familial intrahepatic cholestasis; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; NutropinAq, a liquid formulation of recombinant human growth hormone; Increlex, a recombinant human insulin-like growth factor; Fidrisertib that is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressive; Ritivixibat that is in phase II clinical trial to treat primary sclerosing cholangitis. In addition, it develops neuroscience products, such as Dysport that is in phase III clinical trial for the treatment of chronic and episodic migraine; and IPN10200 that is in phase II to treat aesthetic and therapeutic indications. The company has a partnership with Simcere Zaiming Pharmaceutical Co., Ltd. for the development of SIM0613, a protein expressed on varies tumor types and cancer-associated fibroblasts. The company was founded in 1929 and is headquartered in Paris, France.
0MH6 Stock 12 Month Forecast
Average Price Target
€177.50
▲(10.66% Upside)